Lipigon Pharmaceuticals AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LPGO.ST research report →
Companywww.lipigon.se
Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease and familial chylomicronemia syndrome; a gene therapy project for the lipodystrophy, a rare disease of altered fat distribution in the body; therapeutics for dyslipidemia, a general lipid disorder; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc.
- CEO
- Johan Liwing
- IPO
- 2021
- Employees
- 6
- HQ
- Umeå, SE
Price Chart
Valuation
- Market Cap
- $908.90K
- P/E
- -0.03
- P/S
- 22.72
- P/B
- 0.11
- EV/EBITDA
- 0.29
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -30222.50%
- Op Margin
- -80607.50%
- Net Margin
- -81090.00%
- ROE
- -173.68%
- ROIC
- -407.42%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-32,438,000 · -28.40%
- EPS
- $-0.08 · 55.39%
- Op Income
- $-31,765,000
- FCF YoY
- -43.43%
Performance & Tape
- 52W High
- $0.19
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.06
- Beta
- 0.13
- Avg Volume
- 13.45M
Get TickerSpark's AI analysis on LPGO.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our LPGO.ST Coverage
We haven't published any research on LPGO.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LPGO.ST Report →